Key points are not available for this paper at this time.
May inform carvedilol dosing in arrhythmia patients; leaves open confirmation of class III effects in trials.
The antiarrhythmic drug carvedilol targets hK(2P) 3.1 background channels. We propose that cardiac hK(2P) 3.1 current blockade may suppress electrical automaticity, prolong atrial refractoriness and contribute to the class III antiarrhythmic action in patients treated with the drug.
No takes yet. Share an insight, caveat, or question.
Staudacher et al. (2011) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: